pdufa.bio
HomeDecisions › BAYRY 2026-06-15

BAYRY FDA decision — Jun 15, 2026

✓ APPROVED

Bayer AG ADR — AMBELVIST (gadoquatrane) · Contrast-enhanced magnetic resonance imaging (MRI).

Run-up into the decision (T-120 → T+5)

PDUFA 6/15/26$14.4$9.8812/29/25
Daily close, T-120 (12/29/25) through T+5. Run-up high $14.4 on 2/19/26, low $9.88 on 6/2/26 (T-120 to T-1). FDA decision 6/15/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-15
OutcomeApproved
Drug / candidateAMBELVIST (gadoquatrane)
CompanyBayer AG ADR
120-day run-up (T-120→T-1)-0.1%